Credit Suisse Reiterates Underperform on Humanigen, Maintains $0.5 Price Target
Humanigen Analyst Ratings
Cantor Fitzgerald Reinstates Neutral on Humanigen, Announces $0.15 Price Target
H.C. Wainwright Remains a Hold on Humanigen (HGEN)
Humanigen (HGEN) Gets a Hold from H.C. Wainwright
Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and Humanigen (HGEN)
Humanigen hits 52-week low as Cantor cuts target to $2 on setback for COVID therapy
Humanigen Price Target Cut to $2.00/Share From $13.00 by Roth Capital
Humanigen Cut to Neutral From Buy by Roth Capital
Roth Capital Downgrades Humanigen to Neutral, Lowers Price Target to $2
Cantor Fitzgerald Downgrades Humanigen to Neutral From Overweight, Adjusts Price Target to $2 From 30
Analysts Offer Insights on Healthcare Companies: Humanigen (HGEN), Leap Therapeutics (LPTX) and scPharmaceuticals (SCPH)
Humanigen Price Target Cut to $2.00/Share From $30.00 by Cantor Fitzgerald
Humanigen Cut to Neutral From Overweight by Cantor Fitzgerald
Humanigen Cut to Neutral From Buy by HC Wainwright & Co.
Cantor Fitzgerald Downgrades Humanigen to Neutral, Lowers Price Target to $2
Humanigen analyst ratings
H.C. Wainwright Reiterates Their Buy Rating on Humanigen (HGEN)
No Data